| Promontory Point Rehabilitation | |
| 3909 South 25th East, Ammon, Idaho 83406 | |
| (208) 528-4000 | |
| Name | Promontory Point Rehabilitation |
|---|---|
| Location | 3909 South 25th East, Ammon, Idaho |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 30 |
| Occupancy Rate | 66.33% |
| Medicare ID (CCN) | 135137 |
| Legal Business Name | Snf Ammon Operating Company Llc. |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1760719934 |
| Organization Name | SNF AMMON OPERATING COMPANY LLC. |
| Doing Business As | PROMONTORY POINT REHABILITATION |
| Address | 3909 South 25th East, Ammon, ID 83406 |
| Phone Number | 208-528-4000 |
News Archive
Ranbaxy Laboratories and PPD, Inc. have announced that PPD has acquired an exclusive worldwide license to develop, manufacture and market Ranbaxy's novel statin for the treatment of dyslipidemia.
CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California based contract research and development organization, announced today the signing of a strategic license agreement. This license enables Aragen Bioscience to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient and stable production of preclinical and clinical grade material.
NewYork-Presbyterian Hospital/Columbia University Medical Center has officially opened the Center for Acute Respiratory Failure, which offers, among other services, expertise in using lung bypass technology to help adult patients whose lungs are rapidly shutting down.
Healthcare associated infections, such as catheter related acute bloodstream infections (CLABSI) and ventilator associated pneumonia (VAP), significantly affect hospital morbidity and mortality but by developing evidenced-based, best practices, these occurrences can be minimized, according to research from surgeons at Thomas Jefferson University Hospital.
Research findings published in the Journal of Abnormal Child Psychology have identified differentiating features between early-onset bipolar disorder and combined attention-deficit/hyperactivity disorder.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Ranbaxy Laboratories and PPD, Inc. have announced that PPD has acquired an exclusive worldwide license to develop, manufacture and market Ranbaxy's novel statin for the treatment of dyslipidemia.
CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California based contract research and development organization, announced today the signing of a strategic license agreement. This license enables Aragen Bioscience to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient and stable production of preclinical and clinical grade material.
NewYork-Presbyterian Hospital/Columbia University Medical Center has officially opened the Center for Acute Respiratory Failure, which offers, among other services, expertise in using lung bypass technology to help adult patients whose lungs are rapidly shutting down.
Healthcare associated infections, such as catheter related acute bloodstream infections (CLABSI) and ventilator associated pneumonia (VAP), significantly affect hospital morbidity and mortality but by developing evidenced-based, best practices, these occurrences can be minimized, according to research from surgeons at Thomas Jefferson University Hospital.
Research findings published in the Journal of Abnormal Child Psychology have identified differentiating features between early-onset bipolar disorder and combined attention-deficit/hyperactivity disorder.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $56982 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 3 |
| Experience Measure | Provider | National Avg. |
|---|